Not later than 6 months after , and annually thereafter, the Attorney General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on the Judiciary of the Senate a report on drug shortages that—
section 826(h) of this title identifies the number of requests received under (as added by section 1005 of this Act), the average review time for such requests, the number of requests granted and denied under such section, and, for each of the requests denied under such section, the basis for such denial;
describes the coordination between the Drug Enforcement Administration and Food and Drug Administration on efforts to prevent or alleviate drug shortages; and
section 826 of this title identifies drugs containing a controlled substance subject to when such a drug is determined by the Secretary to be in shortage.
Pub. L. 112–144, title X, § 1006126 Stat. 1105(, , .)
Editorial Notes
References in Text
section 1005 of Pub. L. 112–144section 826 of this titleSection 1005 of this Act, referred to in par. (1), means , which amended .
Codification
Section was enacted as part of the Food and Drug Administration Safety and Innovation Act, and not as part of the Controlled Substances Act which comprises this subchapter.
Statutory Notes and Related Subsidiaries
Definition of “Secretary”
section 1001(b) of Pub. L. 112–144section 356c of this titleThe term “Secretary” as meaning the Secretary of Health and Human Services, see , set out as an Effect of Notification note under .